Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A California cohort study found a 5-year cumulative incidence of metastatic recurrence of 9.5% among adolescents and young adults (AYAs) initially diagnosed with nonmetastatic cancer; recurrence risk and post-recurrence survival varied mark
In a randomized, double‑blind, placebo‑controlled proof‑of‑concept trial, oral engasertib reduced epistaxis frequency and duration in hereditary hemorrhagic telangiectasia (HHT) with a safety profile similar to placebo except for reversible
SURPASS‑ET, a phase 3 randomized trial, showed ropeginterferon alfa‑2b achieved durable ELN responses in 43% of hydroxyurea‑intolerant/refractory ET patients with leukocytosis versus 6% with anagrelide, with a favorable safety profile and f
A Cell study shows head and neck cancers hijack a nerve→lymph node circuit (ATF4→SLIT2→sensory neurons→CGRP) to suppress immunity and cause pain — suggesting nerve-targeting drugs could both ease pain and improve immunotherapy.
In a secondary analysis of the randomized STOP‑CA trial, atorvastatin 40 mg daily attenuated anthracycline‑associated increases in aortic stiffness measured by CMR pulse wave velocity, suggesting vascular protection and a potential strategy
In a multicentre, risk‑adapted phase 2 trial, adding fixed‑duration venetoclax after rituximab‑bendamustine‑cytarabine (RBAC) produced a 2‑year progression‑free survival of 60% in older patients with high‑risk mantle cell lymphoma (MCL). To
A large linkage of Chinese national registries (628.4 million population) estimates 43,275 acute leukaemia cases in 2019, describes age-specific incidence peaks in early childhood and older age, reports major survival gains for children and
The ENAVEN‑AML trial reports that enasidenib combined with venetoclax is feasible and active in relapsed/refractory IDH2‑mutant AML, achieving a 62% overall response rate with manageable toxicity but substantial infectious complications in
A phase 1, single‑arm study evaluated IL‑10–expressing anti‑CD19 CAR T cells in relapsed/refractory B‑ALL, reporting feasibility and encouraging safety signals suggesting attenuated inflammatory toxicity while preserving anti‑leukemic activ
Lupuslike manifestations linked with MDS and CMML differ greatly from classic lupus, featuring unique clinical and molecular traits and often requiring clone-directed treatment rather than standard lupus therapies.
A new ex vivo study shows metformin induces ROS-driven ferroptosis in acute myeloid leukemia (AML), particularly in samples with altered lipid metabolism (IDH2, FLT3 mutations). Lipidomic remodeling, CD36-mediated fatty acid uptake, and DGA
In a population-based Medicare cohort, oncologists preferentially selected higher-clinical-benefit cancer treatments; provider billing margin was not associated with treatment choice, suggesting price or payment reforms that change margins
A multicenter randomized trial found that community health worker support produced modest but durable improvements in health-related quality of life for young adults with sickle cell disease during transition to adult care, whereas a mobile
Applying safety-focused, modernized eligibility criteria to historical AML trials increased patient eligibility from a median of 48% to 84% and reduced racial/ethnic disparities, suggesting pragmatic pathways to improve enrollment and repre
Ramantamig (JNJ-79635322), a trispecific antibody that engages BCMA, GPRC5D and CD3, demonstrates sub-nanomolar cytotoxicity, ex vivo depletion of patient plasma cells, and antitumor activity in xenograft models—supporting ongoing phase 1 t
In a phase 1 study of 18 heavily pretreated patients, the fully human VHH-based anti-GPRC5D CAR T-cell therapy RD118 achieved a 94.4% overall response rate, 72.2% CR/sCR, median PFS 18.2 months, and an acceptable safety profile with predomi
In the ML‑DS 2018 trial, substituting reduced‑intensity induction with CPX‑351 led to lower 24‑month event‑free survival (69% vs 90%) despite excellent overall survival and minimal treatment‑related mortality; MRD by GATA1 NGS, trisomy 8 an
Campus ALL real-world data show that pre-transplant MRD negativity after the pediatric-inspired GIMEMA LAL1913 protocol predicts substantially better 3‑year OS and DFS after alloHSCT; MRD-positive patients and those in CR2 fare markedly wor
The GRAALL‑2014 trial shows that age‑adapted chemotherapy with MRD‑guided alloHSCT reduces early mortality and transplant use while maintaining disease‑free survival in adults (18–59) with Ph‑negative ALL; 4‑year DFS was 57.1% and overall s
Early venetoclax therapy rapidly induces a BAFF-driven upregulation of prosurvival BCL-2 family proteins in surviving CLL cells, suggesting homeostatic cytokine signaling limits depth and durability of response and identifying BAFF/MCL-1 pa
Open language-specific specialty feeds and department pages.